2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2752

Risk of Hospitalizations for Venous Thromboembolism Among Patients with Selected Systemic Vasculitides: A Nationwide Analysis
Abstract Number: 1481

Risk of Ischemic Heart Disease in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis of Observational Studies
Abstract Number: 1480

Risk of Ischemic Stroke in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis
Abstract Number: 2972

Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study
Abstract Number: 1316

Risk of Preterm Delivery Associated with Perinatal Exposure to Dmards in Women with Inflammatory Arthritis: A Population-Based Cohort Study
Abstract Number: 11L

Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Abstract Number: 2274

Risk of Serious Events, Serious Infections, Uveitis, Crohn’s Disease, Colitis and Malignancies in Patients with Juvenile Idiopathic Arthritis on Continuous Treatment with Etanercept over Time: A Report from a Biologics Registry
Abstract Number: 1758

Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Abstract Number: 842

Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards
Abstract Number: 1966

Risk of Tuberculosis in Biologic Users for Rheumatic Diseases: Results from the South African Biologics Registry
Abstract Number: 819

Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
Abstract Number: 18L

Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Abstract Number: 1175

Rituximab for Idiopathic and IgG4-Related Retroperitoneal Fibrosis
Abstract Number: 1757

Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients
Abstract Number: 2402

Rituximab in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 32 Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].